The gene polymorphism of LOX1 predicts the incidence of LVH in patients with essential hypertension

Cellular Physiology and Biochemistry

Volumn 33, Issue 1, 2014, Pages 88-96

  Xu, Xiaolin ^a   Hou, Xuwei ^b   Liang, Yixiu ^c   Li, Fan ^d   Pang, Liewen ^a   Huang, Guoqian ^a   Huang, Jiechun ^a   Shi, Meng ^a   Sun, Xiaotian ^a   Wang, Yiqing ^a  

^a FUDAN UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Essential hypertension; Lectin like oxidized low density lipoprotein receptor 1; Left ventricular hypertrophy; SNP

Indexed keywords

C REACTIVE PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; OLR1 PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; GENE FREQUENCY; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; INCIDENCE; INTRON; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; COMPLICATION; GENETIC PREDISPOSITION; GENETICS; HAPLOTYPE; HEART VENTRICLE; HYPERTENSION; METABOLISM; ORGAN SIZE; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; HOSPITAL BASED CASE CONTROL STUDY; PREDICTION; PROTEIN BLOOD LEVEL;

C-REACTIVE PROTEIN; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; MALE; MIDDLE AGED; ORGAN SIZE; POLYMORPHISM, SINGLE NUCLEOTIDE; ROC CURVE; SCAVENGER RECEPTORS, CLASS E;

EID: 84893205803     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000356652     Document Type: Article

References (42)

1. Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, Giannattasio C, Grassi G, Sega R: Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J Hypertens 2008;26:1602-1611.
2. Petrovic D, Stojimirovic B: [Left ventricular hypertrophy in patients treated with regular hemodialyses]. Med Pregl 2008;61:369-374.
3. Kaplinsky E: Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. Cardiovasc Drugs Ther 1994;8:S549-556.
4. Tovillas-Moran FJ, Vilaplana-Cosculluela M, Zabaleta-del-Olmo E, Dalfo-Baque A, Galceran JM, Coca A: [Cardiovascular morbidity and mortality and electrocardiographic criteria of left ventricular hypertrophy in hypertensive patients treated in primary care]. Med Clin (Barc) 2010;135:397-401.
5. Wang Y, Hou X, Li Y: Association between transforming growth factor beta1 polymorphisms and atrial fibrillation in essential hypertensive subjects. J Biomed Sci 2010;17:23.
6. Zhan S, Liu M, Yao W, Hu Y, Li L, Zhu G, Sun N, Dai L: [Prevalence and relevant factors on echocardiographic left ventricular hypertrophy among community-based hypertensive patients in Shanghai]. Zhonghua Liu Xing Bing Xue Za Zhi 2002;23:182-185.
7. Varis JP, Puukka PJ, Karanko HM, Jula AM: Risk assessment of echocardiographic left ventricular hypertrophy with electrocardiography, body mass index and blood pressure. Blood Press doi:10.3109/080 37051.2013.803313.
8. McNiece KL, Gupta-Malhotra M, Samuels J, Bell C, Garcia K, Poffenbarger T, Sorof JM, Portman RJ: Left ventricular hypertrophy in hypertensive adolescents: analysis of risk by 2004 National High Blood Pressure Education Program Working Group staging criteria. Hypertension 2007;50:392-395.
9. Bangalore S, Yao SS, Chaudhry FA: Usefulness of stress echocardiography for risk stratification and prognosis of patients with left ventricular hypertrophy. Am J Cardiol 2007;100:536-543.
10. Koziolova NA, Shatunova IM, Lazarev IA: [Risk factors of development of left ventricular hypertrophy in patients with hypertensive disease with high compliance to treatment]. Kardiologiia 2012;52:25-30.
11. Villar AV, Llano M, Cobo M, Exposito V, Merino R, Martin-Duran R, Hurle MA, Nistal JF: Gender differences of echocardiographic and gene expression patterns in human pressure overload left ventricular hypertrophy. J Mol Cell Cardiol 2009;46:526-535.
12. Mirotsou M, Dzau VJ, Pratt RE, Weinberg EO: Physiological genomics of cardiac disease: quantitative relationships between gene expression and left ventricular hypertrophy. Physiol Genomics 2006;27:86-94.
13. Kurbanova D, Eliseyeva M: Genetic background of left ventricular hypertrophy in Uzbek hypertensive men. Turk Kardiyol Dern Ars 2010;38:466-472.
14. El-Shehaby AM, El-Khatib MM, Marzouk S, Battah AA: Relationship of BsmI polymorphism of vitamin D receptor gene with left ventricular hypertrophy and atherosclerosis in hemodialysis patients. Scand J Clin Lab Invest 2013; 73:75-81.
15. Kaufman BD, Desai M, Reddy S, Osorio JC, Chen JM, Mosca RS, Ferrante AW, Mital S: Genomic profiling of left and right ventricular hypertrophy in congenital heart disease. J Card Fail 2008;14:760-767.
16. Xu HY, Hou XW, Wang LF, Wang NF, Xu J: Association between transforming growth factor beta1 polymorphisms and left ventricle hypertrophy in essential hypertensive subjects. Mol Cell Biochem 2010;335:13-17.
17. Hou XW, Jiang Y, Wang LF, Xu HY, Lin HM, He XY, He JJ, Zhang S: Protective role of granulocyte colony-stimulating factor against adriamycin induced cardiac, renal and hepatic toxicities. Toxicol Lett 2009;187:40-44.
18. Inoue N, Fujita Y, Sawamura T: [Progress in the research on Lox-1 and its clinical relevance]. Nihon Yakurigaku Zasshi 2006;127:103-108.
19. Al-Banna N, Lehmann C: Oxidized LDL and LOX-1 in experimental sepsis. Mediators Inflamm 2013;2013:761789.
20. Fujita Y, Kakino A, Nishimichi N, Yamaguchi S, Sato Y, Machida S, Cominacini L, Delneste Y, Matsuda H, Sawamura T: Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem 2009;55:285-294.
21. Hou XW, Son J, Wang Y, Ru YX, Lian Q, Majiti W, Amazouzi A, Zhou YL, Wang PX, Han ZC: Granulocyte colony-stimulating factor reduces cardiomyocyte apoptosis and improves cardiac function in adriamycin-induced cardiomyopathy in rats. Cardiovasc Drugs Ther 2006;20:85-91.
22. Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, Zerkowski HR, Sawamura T, Holtz J: Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999;100:899-902.
23. Kang BY, Hu C, Ryu S, Khan JA, Biancolella M, Prayaga S, Seung KB, Novelli G, Mehta P, Mehta JL: Genomics of cardiac remodeling in angiotensin II-treated wild-type and LOX-1-deficient mice. Physiol Genomics 2010;42:42-54.
24. Hu C, Dandapat A, Chen J, Fujita Y, Inoue N, Kawase Y, Jishage K, Suzuki H, Sawamura T, Mehta JL: LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion. Cardiovasc Res 2007;76:292-302.
25. Hu C, Dandapat A, Sun L, Khan JA, Liu Y, Hermonat PL, Mehta JL: Regulation of TGFbeta1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFbeta1 in wild-type and lox-1 knock-out mouse cardiac fibroblasts. J Biol Chem 2008;283:10226-10231.
26. Aoyama T, Sawamura T, Furutani Y, Matsuoka R, Yoshida MC, Fujiwara H, Masaki T: Structure and chromosomal assignment of the human lectin-like oxidized low-density-lipoprotein receptor-1 (LOX-1) gene. Biochem J 1999;339:177-184.
27. Chen Q, Reis SE, Kammerer C, Craig WY, LaPierre SE, Zimmer EL, McNamara DM, Pauly DF, Sharaf B, Holubkov R, Bairey Merz CN, Sopko G, Bontempo F, Kamboh MI: Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease. Circulation 2003;107:3146-3151.
28. Hou XW, Yang RQ, Zhong YG, Gao W, Sun SP, Wang NF: G501C polymorphism of the oxidized LDL receptor gene is associated with albuminuria in Chinese essential hypertension patients. Genet Mol Res 2011;10.
29. Hou XW, Wang LF, Wang N, Pang D, Hui B, Zhou YL, He X: The G501C polymorphism of oxidized LDL receptor gene [OLR-1] is associated with susceptibility and serum C-reactive protein concentration in Chinese essential hypertensives. Clin Chim Acta 2008;388:200-203.
30. Trabetti E, Biscuola M, Cavallari U, Malerba G, Girelli D, Olivieri O, Martinelli N, Corrocher R, Pignatti PF: On the association of the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction or coronary artery disease. Eur J Hum Genet 2006;14:127-130.
31. Li JJ, Chen JL: Inflammation may be a bridge connecting hypertension and atherosclerosis. Med Hypotheses 2005;64:925-929.
32. Virdis A, Schiffrin EL: Vascular inflammation: a role in vascular disease in hypertension? Curr Opin Nephrol Hypertens 2003;12:181-187.
33. Tatsuguchi M, Furutani M, Hinagata J, Tanaka T, Furutani Y, Imamura S, Kawana M, Masaki T, Kasanuki H, Sawamura T, Matsuoka R: Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem Biophys Res Commun 2003;303:247-250.
34. Ohmori R, Momiyama Y, Nagano M, Taniguchi H, Egashira T, Yonemura A, Nakamura H, Kondo K, Ohsuzu F: An oxidized low-density lipoprotein receptor gene variant is inversely associated with the severity of coronary artery disease. Clin Cardiol 2004;27:641-644.
35. Ohki I, Ishigaki T, Oyama T, Matsunaga S, Xie Q, Ohnishi-Kameyama M, Murata T, Tsuchiya D, Machida S, Morikawa K, Tate S: Crystal structure of human lectin-like, oxidized low-density lipoprotein receptor 1 ligand binding domain and its ligand recognition mode to OxLDL. Structure 2005;13:905-917.
36. Hattori H, Sonoda A, Sato H, Ito D, Tanahashi N, Murata M, Saito I, Watanabe K, Suzuki N: G501C polymorphism of oxidized LDL receptor gene (OLR1) and ischemic stroke. Brain Res 2006;1121:246-249.
37. Meucci MA, Marsh S, Watters JW, McLeod HL: CEPH individuals are representative of the European American population: implications for pharmacogenetics. Pharmacogenomics 2005;6:59-63.
38. Hein TW, Qamirani E, Ren Y, Xu X, Thengchaisri N, Kuo L: Selective Activation of LOX-1 Mediates C-Reactive Protein Evoked Endothelial Vasodilator Dysfunction in Coronary Arterioles. Circ Res 2013;114:92-100.
39. Chu C-S, Wang Y-C, Lu L-S, Walton B, Yilmaz HR, Huang RY, Sawamura T, Dixon RAF, Lai W-T, Chen C-H, Lu J: Electronegative Low-Density Lipoprotein Increases C-Reactive Protein Expression in Vascular Endothelial Cells through the LOX-1 Receptor. PLoS ONE 2013;8:e70533.
40. Lu J, Yang JH, Burns AR, Chen HH, Tang D, Walterscheid JP, Suzuki S, Yang CY, Sawamura T, Chen CH: Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis. Circ Res 2009;104:619-627.
41. Lu J, Jiang W, Yang JH, Chang PY, Walterscheid JP, Chen HH, Marcelli M, Tang D, Lee YT, Liao WS, Yang CY, Chen CH: Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting fibroblast growth factor 2 (FGF2) autoregulation. Diabetes 2008;57:158-166.
42. Fujita Y, Yamaguchi S, Kakino A, Iwamoto S, Yoshimoto R, Sawamura T: Lectin-like Oxidized LDL Receptor 1 Is Involved in CRP-Mediated Complement Activation. Clin Chem 2011;57:1398-1405.